Navigation Links
Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
Date:11/8/2011

DURHAM, N.C., Nov. 8, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent® Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release. Four, six and eight month data from the DESSOLVE I trial were presented at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2011) by John Ormiston, M.D., Mercy Angiography Unit, Auckland, New Zealand, a principal investigator in the study. TCT will make the presentation available on its website at www.tctmd.com following the conference.

"These preliminary study results demonstrated excellent performance by the MiStent DES at up to eight months post-procedure -- when patients typically experience the greatest increase in neointimal hyperplasia," said Dr. Ormiston. "MiStent DES is intended to provide enhanced patient safety and outcome by eliminating long-term exposure to DES non-erodible polymers. In addition to delivering clinical performance, MiStent DES may also enable physicians to pursue shorter duration dual anti-platelet therapy, and offer a safer choice to their non-compliant patients or patients who may be undergoing additional surgical procedures."  

Thirty patients were treated with the MiStent DES with independent subgroups of 10 patients assigned to a four month, six month or eight month follow-up. The primary efficacy endpoint was in-stent late lumen loss (LLL). Safety was assessed by incidence of major adverse cardiac events (MACE) and presence of tissue coverage within the treated artery at each time point. Angiography, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging results were measured by independent core laboratories. Preliminary analysis of the data demonstrated a very low median
'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micell Technologies Announces Presentation of Clinical Data at TCT 2011
2. Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent
3. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
4. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
5. BioMarCare Technologies Ltd. Granted Access to Archived Samples in the Hadassah Medical Center
6. Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
7. Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair
8. China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011
9. AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
10. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
11. Connectyx Technologies to Host Teleconference on Third Quarter Financial Results on Tuesday November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... SOUTHAMPTON, England, March 24 , ... Completes Phase I Dosing , ... medical needs, announces further clinical trial progress with its ... hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa,trial ...
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
Cached Medicine Technology:Vantia Therapeutics' Pipeline Continues to Mature 2Vantia Therapeutics' Pipeline Continues to Mature 3Vantia Therapeutics' Pipeline Continues to Mature 4Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... published in the August issue of the American Journal ... multidetector computed tomography (MDCT) in diagnosing// the spread of ... MDCT on 69 patients to examine the efficiency of ... of the 44 cases, while MDCT correctly diagnosed 27. ...
... at a local hospital in Tulungagung, East Java, became ... yesterday.// Runizar Ruesin from the health ministry's bird flu ... with dead chickens. ,Local tests confirmed that ... to deal with bird flu infection and the human ...
... September is the World Heart Day. The theme for the ... all, especially the youth//, to follow a health-friendly regime and ... ,A healthy heart is the foundation to a healthy ... to a healthy life. The booming IT industry, with its ...
... of Fresno, is going through a rough patch, following a ... was enforced after three children from South California took ill ... the State’s charge said "There's a lot of confusion. The ... it's an over-reaction." , ,The State Department of Food ...
... to focus more on healthy eating could be accomplished ... children to eat healthier food could lead to clashes ... has been unveiled by the government which is aimed ... to shorter life expectancies in the younger generation than ...
... Health & Science University's (OHSU) Doernbecher Children's Hospital, the ... to cure Batten disease// is set to get underway ... but deadly neurodegenerative disorder. A phase I trial is ... of its efficacy.,According to the researchers, the transplants of ...
Cached Medicine News:Health News:Healthy Heart for a Hearty Life 2Health News:$67m to Tackle Obesity 2Health News:Stem cell trial to beat Batten Disease 2Health News:Stem cell trial to beat Batten Disease 3
Fine pointed grooved jaws with smooth curve from tip to finger grip style handle. Dull finish....
This forcep was designed to eliminate the occasional tearing of tissue which may occur when grasping the lips of an incision with a traditional. 12 forceps. The rows of blunt teeth are gentle yet pro...
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with 90 degrees, 2 x 3 teeth and tying platform. Serrated handle with polished finish. Most popular size or model....
Medicine Products: